AAO: Wouldn't it be Great if Eyedrops Didn't Spill Out of Your Eyes?
Read full story
BioTime has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (IIA) to fund the continued development of OpRege…Read the full story
BioTime announced that an abstract related to the company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being …Read the full story
BioTime reported several developments for its ophthalmology portfolio, including: Signing a new and expanded licensing agreement with Hadassah Medical Organization of Jerusalem, Israel Present…Read the full story
BioTime announced that a poster related to the company’s retinal restoration technology was presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in …Read the full story
BioTime announced new data from the phase 1/2a clinical trial of OpRegen in the advanced form of dry age-related macular degeneration (AMD). The interim data were presented on May 8, 2017 at the …Read the full story